Buprenorphine hydrochloride

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C29H41NO4.ClH
Molecular Weight	504.101
Optical Activity	( - )
Defined Stereocenters	7 / 7
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of Buprenorphine hydrochloride

Structure Search

SMILES

Cl.CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4CC5=C6C(O[C@@H]2[C@@]36CCN4CC7CC7)=C(O)C=C5

InChI

InChIKey=UAIXRPCCYXNJMQ-RZIPZOSSSA-N

InChI=1S/C29H41NO4.ClH/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28;/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3;1H/t20-,21-,24-,26+,27-,28+,29-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C29H41NO4
Molecular Weight	467.6401
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	7 / 7
E/Z Centers	0
Optical Activity	( - )

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020732s014s015lbl.pdf

Buprenorphine is an opioid analgesic, used to treat opioid addiction, moderate acute pain, and moderate chronic pain. Buprenorphine is a partial agonist at the mµ-opioid receptor and an antagonist at the kappa-opioid receptor. One unusual property of buprenorphine observed in vitro studies is its very slow rate of dissociation from its receptor. This could account for its longer duration of action than morphine, the unpredictability of its reversal by opioid antagonists, and its low level of manifest physical dependence. The principal action of the therapeutic value of buprenorphine is analgesia and is thought to be due to buprenorphine binding with high affinity to opioid receptors on neurons in the brain and spinal cord. Buprenorphine produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and electrical stimulation. Buprenorphine causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Buprenorphine produces peripheral vasodilation, which may result in orthostatic hypotension or syncope. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Mu opioid receptor 231 Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24903063	Partial Agonist 297	1.5 nM [Ki]
Kappa opioid receptor 115 Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24903063	Antagonist 2849	2.5 nM [Ki]
Delta opioid receptor 81 Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24903063	Antagonist 2849	6.1 nM [Ki]
Nociceptin receptor 14 Target ID: P41146 Gene ID: 4987.0 Gene Symbol: OPRL1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24903063	Partial Agonist 297	77.4 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Chronic pain 9 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021306s000lbl.pdf	Primary	Approved 8583	BUTRANS Approved Use SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence. Prescription use of this product is limited under the Drug Addiction Treatment Act. (1) Launch Date 2010
Opioid dependence 21 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020732s014s015lbl.pdf	Primary	Approved 8583	BUTRANS Approved Use SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence. Prescription use of this product is limited under the Drug Addiction Treatment Act. (1) Launch Date 2010
Osteoarthritis 157 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021306s000lbl.pdf	Primary	Phase IV 63	BUTRANS Approved Use SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence. Prescription use of this product is limited under the Drug Addiction Treatment Act. (1) Launch Date 2010
Rheumatoid arthritis 320 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021306s000lbl.pdf	Primary	Phase IV 63	BUTRANS Approved Use SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence. Prescription use of this product is limited under the Drug Addiction Treatment Act. (1) Launch Date 2010
Lower back pain 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021306s000lbl.pdf	Primary	Phase IV 63	BUTRANS Approved Use SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence. Prescription use of this product is limited under the Drug Addiction Treatment Act. (1) Launch Date 2010

C_max

Value	Dose	Co-administered	Analyte	Population
0.17 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207932s012lbl.pdf	75 μg single, oral dose: 75 μg route of administration: Oral experiment type: SINGLE co-administered:		BUPRENORPHINE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
0.63 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207932s012lbl.pdf	75 μg single, oral dose: 75 μg route of administration: Oral experiment type: SINGLE co-administered:		BUPRENORPHINE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
3 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207932s012lbl.pdf	75 μg single, oral dose: 75 μg route of administration: Oral experiment type: SINGLE co-administered:		BUPRENORPHINE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
4% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207932s012lbl.pdf	75 μg single, oral dose: 75 μg route of administration: Oral experiment type: SINGLE co-administered:		BUPRENORPHINE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
5.714 ug/kg 1 times / day single, intravenous Studied dose Dose: 5.714 ug/kg, 1 times / day Route: intravenous Route: single Dose: 5.714 ug/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207932s000lbl.pdf https://pubmed.ncbi.nlm.nih.gov/16547090/	healthy, 22 to 35 years Health Status: healthy Age Group: 22 to 35 years Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207932s000lbl.pdf https://pubmed.ncbi.nlm.nih.gov/16547090/	Other AEs: Respiratory depression... Other AEs: Respiratory depression Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207932s000lbl.pdf https://pubmed.ncbi.nlm.nih.gov/16547090/
480 ug 2 times / day multiple, oral Recommended Dose: 480 ug, 2 times / day Route: oral Route: multiple Dose: 480 ug, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf	Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (4.4%) Vomiting (1.6%) Constipation (0.8%) Dizziness (1.4%) Headache (1.1%) Somnolence (1.1%) Fatigue (0.8%) QT interval prolonged (0.5%) Anxiety (0.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
32 mg 1 times / day single, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: single Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8181201/	healthy, mean age 32.3 years Health Status: healthy Age Group: mean age 32.3 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/8181201/	Sources: https://pubmed.ncbi.nlm.nih.gov/8181201/
0.125 mg 3 times / day multiple, sublingual Dose: 0.125 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.125 mg, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02634788	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT02634788	Other AEs: Nausea, Vomiting... Other AEs: Nausea (below serious, 36 patients) Vomiting (below serious, 24 patients) Constipation (below serious, 9 patients) Dizziness (below serious, 18 patients) Headache (below serious, 15 patients) Somnolence (below serious, 6 patients) Pruritus (below serious, 2 patients) Hyperhidrosis (below serious, 2 patients) Oxygen saturation decreased (below serious, 6 patients) Hot flush (below serious, 2 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT02634788
0.25 mg 3 times / day multiple, sublingual Dose: 0.25 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.25 mg, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02634788	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT02634788	Other AEs: Nausea, Vomiting... Other AEs: Nausea (below serious, 47 patients) Vomiting (below serious, 33 patients) Constipation (below serious, 6 patients) Dizziness (below serious, 26 patients) Headache (below serious, 23 patients) Somnolence (below serious, 6 patients) Pruritus (below serious, 2 patients) Hyperhidrosis (below serious, 1 patient) Oxygen saturation decreased (below serious, 8 patients) Hot flush (below serious, 2 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT02634788
0.5 mg 3 times / day multiple, sublingual Dose: 0.5 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.5 mg, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02634788	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT02634788	Other AEs: Angioedema, Nausea... Other AEs: Angioedema (serious, 1 patient) Nausea (below serious, 68 patients) Vomiting (below serious, 59 patients) Constipation (below serious, 8 patients) Dizziness (below serious, 44 patients) Headache (below serious, 13 patients) Somnolence (below serious, 11 patient) Pruritus (below serious, 11 patient) Hyperhidrosis (below serious, 8 patients) Oxygen saturation decreased (below serious, 7 patients) Dehydration (below serious, 7 patients) Hot flush (below serious, 5 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT02634788

AEs

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3216	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3216
ZINC	ZINC000001319780	http://zinc15.docking.org/substances/ZINC000001319780

PubMed

Title	Date	PubMed
[Treatment of heroin addiction--clinical findings hand-in-hand with evidence].	2001-10-10	11699259
Buprenorphine: better late than never.	2001-10-01	11700809
Hydrolysis of conjugated metabolites of buprenorphine. I. The quantitative enzymatic hydrolysis of buprenorphine-3-beta-D-glucuronide in human urine.	2001-10	11599605
Opioid maintenance: the politics matter.	2001-10	11599514
Cost-effectiveness of buprenorphine maintenance versus methadone maintenance.	2001-10	11599513
Cost-effectiveness estimates for buprenorphine should factor in crime.	2001-10	11599512
Comparison of methadone and high dosage buprenorphine users in French care centres.	2001-10	11571062
Effect of epidural analgesia on postoperative paralytic ileus in chronic schizophrenia.	2001-09-19	11561267
Deaths involving buprenorphine: a compendium of French cases.	2001-09-15	11516889
[Use of a new drug in the treatment of heroin addicts should not be obstructed by political dogmatism].	2001-09-12	11586837
Port-site recurrence reproduced in the VX-2 rabbit carcinoma model: an in vivo model comparing laparoscopic port sites and open incisions.	2001-09-11	11548826
Limits to buprenorphine dosing: a comparison between quintuple and sextuple the maintenance dose every 5 days.	2001-09-01	11470347
The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States.	2001-09	11672491
[Continuous epidural administration of droperidol for the prevention of postoperative nausea].	2001-09	11593710
Preoperative blood pressure and intraoperative hypothermia during lower abdominal surgery.	2001-09	11576056
Effects of medetomidine and buprenorphine administered for sedation in dogs.	2001-09	11570387
HS-599: a novel long acting opioid analgesic does not induce place-preference in rats.	2001-09	11564664
[Buprenorphine in pregnancy].	2001-09	11533891
[Review of scientific evidence on alternatives to methadone in the psychopharmacologic treatment of opiate dependence].	2001-08-23	11515335
[A national model for drug-supported rehabilitation of opiate addicts].	2001-08-20	11571885
Buprenorphine for opiate addiction: potential economic impact.	2001-08-01	11418229
[The influence of age on hemodynamics and the dose requirements of propofol and buprenorphine in total intravenous anesthesia combined with continuous epidural anesthesia].	2001-08	11554014
[The benefit of combining spinal morphine and intravenous buprenorphine for perioperative pain].	2001-08	11547472
Age-related differences in sensitivity to the antinociceptive effects of opioids in male rats. Influence of nociceptive intensity and intrinsic efficacy at the mu receptor.	2001-08	11498722
Office-based treatment for opioid dependence: reaching new patient populations.	2001-08	11481150
Effect of perinatal buprenorphine exposure on development in the rat.	2001-08	11454944
Rapid heroin detoxification using a single high dose of buprenorphine.	2001-07-31	11476266
Buprenorphine added to the local anesthetic for brachial plexus block to provide postoperative analgesia in outpatients.	2001-07-21	11464356
Opioid chronopharmacology.	2001-07	11531909
[The effect of intravenous patient controlled analgesia on activities of daily life and medical expense after thoracotomy].	2001-07	11510062
Influence of buprenorphine analgesia on post-operative recovery in two strains of rats.	2001-07	11459404
Testing and comparison of non-opioid analgesics in amphibians.	2001-07	11451391
The antinociceptive effect of the combination of spinal morphine with systemic morphine or buprenorphine.	2001-07	11429365
Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.	2001-07	11408532
Perceptual and motor effects of morphine and buprenorphine in baboons.	2001-06-23	11420099
Electrically-assisted transdermal delivery of buprenorphine.	2001-06-15	11516497
An exploratory study of buprenorphine use in Bangladesh: a note.	2001-06	11504153
Epidural analgesia with a combination of bupivacaine and buprenorphine in rats.	2001-06	11475905
[Usefulness of epidural infusion of ketamine for relief of localized superficial pain].	2001-06	11452479
Three-choice discrimination in pigeons is based on relative efficacy differences among opioids.	2001-06	11441428
Narcotic analgesia in the acute abdomen--a review of prospective trials.	2001-06	11436909
A new era in opioid dependency treatment. Recent law allows qualified physicians to provide care in office setting.	2001-06	11424343
[Anesthetic management of two patients with essential thrombocythemia].	2001-05	11424477
[Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)].	2001-04	11435992
[Reduction in the number of lethal heroin overdoses in France since 1994. Focus on substitution treatments].	2001-04	11435989
The use of analgesic drugs by South African veterinarians.	2001-03	11563724
SUNCT syndrome: a treatment option with local opioid blockade of the superior cervical ganglion? A case report.	2001-03	11422100
Opioid antagonists for smoking cessation.	2001	11687036
[Use of buprenorphine as a substitute treatment for opiate dependence in the Toxicology Clinics--introductory clinical report].	2001	11450367
Gradual dose taper following chronic buprenorphine.	2001	11444154

Patents

Sample Use Guides

In Vivo Use Guide

The initial starting dose is 1 mL buprenorphine hydrochloride injection (0.3 mg buprenorphine) given by deep intramuscular or slow (over at least 2 minutes) intravenous injection at up to 6-hour intervals, as needed. Repeat once (up to 0.3 mg) if required, 30 to 60 minutes after initial dosage, giving consideration to previous dose pharmacokinetics, and thereafter only as needed. In high-risk patients (e.g., elderly, debilitated, presence of respiratory disease, etc.) and/or in patients where other CNS depressants are present, such as in the immediate postoperative period, the dose should be limited to the minimum required. Buprenorphine hydrochloride has been used in pediatric patients 2 to 12 years of age at doses between 2 to 6 micrograms/kg of body weight given every 4 to 6 hours. There is insufficient experience to recommend a dose in infants below the age of two years, single doses greater than 6 micrograms/kg of body weight, or the use of a repeat or second dose at 30 to 60 minutes (such as is used in adults).

Route of Administration: Other

In Vitro Use Guide

Functional activity of μ receptors in intact cells was determined by measuring receptor-induced membrane potential change, which can be directly read by Molecular Devices Membrane Potential Assay Kit (Blue Dye) using the FlexStation 3® microplate reader. CHO cells transfected with human μ-opioid receptors were seeded in a 96-well plate (30 000 cells per well) 1 day prior to the experiments. For agonist assays, after brief washing, the cells were loaded with 225 μL of HBSS assay buffer (HBSS with 20 mM of HEPES, pH 7.4), containing the blue dye, and incubated at 37°C. After 30 min, 25 μL of the Buprenorphine were automatically dispensed into the wells by the FlexStation and receptor stimulation-mediated membrane potential change is recorded every 3 s for 60 s by reading 550–565 nm fluorescence excited at 530 nm wavelength.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:51:13 GMT 2025` Edited by `admin` on `Mon Mar 31 17:51:13 GMT 2025`
Record UNII	56W8MW3EN1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Buprenorphine hydrochloride CIII

Preferred Name

English

Buprenorphine hydrochloride

Official Name

English

Bunavail component buprenorphine hydrochloride

Brand Name

English

CL-112302

Code

English

SUBOXONE COMPONENT BUPRENORPHINE HYDROCHLORIDE

Common Name

English

CL 112,302

Code

English

RX-6029-M HCL

Code

English

Belbuca

Brand Name

English

NOPAN

Brand Name

English

FINIBRON

Brand Name

English

LEPETAN

Common Name

English

Buprex

Common Name

English

VETERGESIC

Common Name

English

Buprenorphine hydrochloride [USAN]

Common Name

English

Buprenorphine hydrochloride [JAN]

Common Name

English

Buprenorphine hydrochloride[ORANGE BOOK]

Common Name

English

Buprederm

Common Name

English

6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-?-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-?-methyl-, hydrochloride, [5?,7?(S)]-

Systematic Name

English

Anorfin

Brand Name

English

NIH-8805

Code

English

RX6029-M HCL

Code

English

Buprenorphine hydrochloride [EP MONOGRAPH]

Common Name

English

Buprenorphine hydrochloride [MART.]

Common Name

English

6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-?-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-?-methyl-, hydrochloride (1:1), (?S,5?,7?)-

Systematic Name

English

Buprenorphine hydrochloride [USP-RS]

Common Name

English

Buprenorphine hydrochloride [USP IMPURITY]

Common Name

English

Buprenex

Brand Name

English

UM 952

Code

English

Buprenorphine hydrochloride [WHO-DD]

Common Name

English

SCH-028444

Code

English

Buprenorphine hydrochloride [MI]

Common Name

English

SUBUTEX

Brand Name

English

Buprenorphine hydrochloride [VANDF]

Common Name

English

Buprenorphine HCL

Common Name

English

NIH8805

Code

English

Buprenorphine hydrochloride [USP MONOGRAPH]

Common Name

English

21-Cyclopropyl-7?-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine hydrochloride

Systematic Name

English

Buprenorphine hydrochloride [EP IMPURITY]

Common Name

English

M-6029

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C67413